Okay. Just one quick point about how the rules did not work, which I think responds a little bit to the question you had raised earlier, Mr. Garneau, and it is related to this as well. It's providing information by Rachel Kiddell-Monroe, who's involved in this. We couldn't actually go forward with our process without a named country, and that was a real barrier, so that was an error in the process that did not work. I think the pharmaceutical industry perspective on this is that patents are not a barrier because there are voluntary mechanisms that can be used.
I just wanted to respond to that and say that voluntary mechanisms generally are not voluntary entirely. They usually exist because of pressure either from litigation or from the threat of a compulsory licence. There's certainly value to the threat of a compulsory licence, and there were a number of different examples of this, such as in South Africa when there was a competition commission challenge and in India when there was pre-grant patent opposition. Those are when voluntary licences get issued and when these collaborations exist.